Innovative Cancer Treatments AgilVax is actively developing targeted antibody-based therapeutics, specifically AX09, for treating metastatic breast cancer and triple negative breast cancer, presenting opportunities to collaborate on novel cancer treatment solutions.

Research & Development Focus With partnerships such as Leidos for malaria vaccine development, AgilVax demonstrates an opening for supporting its R&D efforts or providing complementary biotech solutions to accelerate their pipeline.

Recent Leadership Expansion The appointment of experienced executives like Joseph Patti and new board members presents a chance to engage with leadership for strategic partnerships or investor relations to support company growth and innovation.

Funding & Revenue Growth Although a smaller firm with revenue between 1M and 10M and funding at 1.5M, AgilVax's focus on impactful cancer therapies indicates potential for scalable collaborations or investment opportunities as they advance their product pipeline.

Market Position & Potential Operating with a lean team of 11 to 50 employees in biotech research, AgilVax's focus on cutting-edge therapeutics offers prospects for partnership in clinical trials, research support, or supply chain services to aid in their development process.